Alumis Inc. (ALMS): who owns it and who trades it
As of Nov 16, 2026, ALMS insiders reported 15 open-market sales worth $1.6M and 24 purchases worth $36.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Srinivas Akkaraju (Director), with $1M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Alumis
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ALMS
199 funds and institutions reported ALMS shares worth $3.4B at the end of Q2 2026. The largest holder is AyurMaya Capital Management Company, LP with $426M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| AyurMaya Capital Management Company, LP | 15.14M | – | $426M | – |
| BlackRock, Inc. | 8.22M | – | $231M | +15% |
| FMR LLC (Fidelity) | 6.77M | – | $190M | +595% |
| Deep Track Capital, LP | 6.35M | – | $179M | -6% |
| Samsara Biocapital, LLC | 6.35M | – | $179M | No change |
| Foresite Capital Management V, LLC | 5.90M | – | $166M | No change |
| T. Rowe Price Associates | 5.20M | – | $146M | +58% |
| VenBio Partners LLC | 4.53M | – | $127M | No change |
| Foresite Capital Management VI LLC | 4.25M | – | $120M | No change |
| Vanguard Capital Management LLC | 4.22M | – | $119M | +5% |
| Nextech Invest Ltd. | 3.54M | – | $99.6M | No change |
| Cormorant Asset Management, LP | 3.29M | – | $92.5M | -17% |
| Saturn V Capital Management LP | 2.92M | – | $82M | -9% |
| Octagon Capital Advisors LP | 2.83M | – | $79.7M | No change |
| Jupiter Topco LLC | 2.36M | – | $66.2M | – |
| California State Teachers Retirement System | 2.22M | – | $78.8M | +2643% |
| State Street Corp | 2.19M | – | $61.5M | +21% |
| Geode Capital Management, LLC | 2.17M | – | $61M | +13% |
| Mpm Bioimpact LLC | 2.02M | – | $56.8M | -15% |
| Baker Bros. Advisors LP | 2.01M | – | $56.6M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ALMS insiders reported $36.5M of open-market purchases and $1.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Roy C. Hardiman | Chief Business & Strateg | Sale | 652 | $6.52 | $4.3K | Form 4 |
| Nov 2, 2026 | John R. Schroer | CFO | Sale | 794 | $6.52 | $5.2K | Form 4 |
| Nov 2, 2026 | David M Goldstein | Chief Scientific Officer | Sale | 629 | $6.52 | $4.1K | Form 4 |
| Nov 2, 2026 | Jorn Drappa | Chief Medical Officer | Sale | 593 | $6.52 | $3.9K | Form 4 |
| Nov 2, 2026 | Mark Christopher Bradley | Chief Development Office | Sale | 623 | $6.52 | $4.1K | Form 4 |
| Nov 2, 2026 | Sanam Pangali | Chief Legal Officer | Sale | 332 | $6.52 | $2.2K | Form 4 |
| Sep 8, 2026 | Srinivas Akkaraju | Director | Sale | 48,066 | $10.55 | $507K | Form 4 |
| Sep 8, 2026 | Srinivas Akkaraju | Director | Purchase | 273,291 | $10.63 | $2.9M | Form 4 |
| Sep 8, 2026 | Srinivas Akkaraju | Director | Purchase | 273,290 | $10.63 | $2.9M | Form 4 |
| Sep 8, 2026 | Srinivas Akkaraju | Director | Sale | 48,065 | $10.55 | $507K | Form 4 |
| Sep 4, 2026 | Srinivas Akkaraju | Director | Purchase | 220,070 | $11.17 | $2.5M | Form 4 |
| Aug 3, 2026 | John R. Schroer | CFO | Sale | 3,282 | $26.37 | $86.5K | Form 4 |
| Aug 3, 2026 | Sanam Pangali | Chief Legal Officer | Sale | 1,364 | $26.37 | $36K | Form 4 |
| Aug 3, 2026 | Roy C. Hardiman | Chief Business & Strateg | Sale | 2,692 | $26.37 | $71K | Form 4 |
| Aug 3, 2026 | David M Goldstein | Chief Scientific Officer | Sale | 2,596 | $26.37 | $68.5K | Form 4 |
| Aug 3, 2026 | Jorn Drappa | Chief Medical Officer | Sale | 2,447 | $26.37 | $64.5K | Form 4 |
| Aug 3, 2026 | Mark Christopher Bradley | Chief Development Office | Sale | 2,572 | $26.37 | $67.8K | Form 4 |
| Jul 6, 2026 | Sanam Pangali | Chief Legal Officer | Sale | 5,000 | $28.00 | $140K | Form 4 |
| Jan 9, 2026 | Srinivas Akkaraju | Director | Purchase | 588,235 | $17.00 | $10M | Form 4 |
| Jan 8, 2026 | Foresite Labs, LLC +1 | 10% owner | Purchase | 117,647 | $17.00 | $2M | Form 4 |
| Jan 8, 2026 | Foresite Labs, LLC +1 | 10% owner | Purchase | 294,117 | $17.00 | $5M | Form 4 |
| Dec 5, 2025 | Srinivas Akkaraju | Director | Purchase | 70,028 | $10.01 | $701K | Form 4 |
| Dec 5, 2025 | Srinivas Akkaraju | Director | Purchase | 51,380 | $10.73 | $551K | Form 4 |
| Dec 5, 2025 | Srinivas Akkaraju | Director | Purchase | 64,969 | $8.95 | $581K | Form 4 |
| Dec 4, 2025 | Srinivas Akkaraju | Director | Purchase | 66,027 | $8.18 | $540K | Form 4 |
| Dec 3, 2025 | Srinivas Akkaraju | Director | Purchase | 100,000 | $7.75 | $775K | Form 4 |
| Dec 2, 2025 | Srinivas Akkaraju | Director | Purchase | 96,000 | $7.55 | $725K | Form 4 |
| Dec 1, 2025 | Srinivas Akkaraju | Director | Purchase | 86,350 | $7.46 | $644K | Form 4 |
| Nov 28, 2025 | Srinivas Akkaraju | Director | Purchase | 38,702 | $7.64 | $296K | Form 4 |
| Nov 26, 2025 | Srinivas Akkaraju | Director | Purchase | 48,537 | $7.64 | $371K | Form 4 |
| Nov 21, 2025 | Foresite Labs Fund I, L.P. +8 | 10% owner | Purchase | 72,212 | $7.38 | $533K | Form 4 |
| Nov 20, 2025 | Srinivas Akkaraju | Director | Purchase | 125,743 | $7.20 | $905K | Form 4 |
| Nov 19, 2025 | Foresite Labs Affiliates 2021, LLC +1 | 10% owner | Purchase | 190,500 | $6.56 | $1.2M | Form 4 |
| Nov 19, 2025 | Srinivas Akkaraju | Director | Purchase | 137,772 | $6.56 | $904K | Form 4 |
| Nov 18, 2025 | Foresite Labs Affiliates 2021, LLC +1 | 10% owner | Purchase | 117,374 | $6.19 | $727K | Form 4 |
| Nov 18, 2025 | Srinivas Akkaraju | Director | Purchase | 102,652 | $6.05 | $621K | Form 4 |
| Nov 17, 2025 | Foresite Labs Affiliates 2021, LLC +1 | 10% owner | Purchase | 50,000 | $5.60 | $280K | Form 4 |
| Nov 17, 2025 | Foresite Labs Affiliates 2021, LLC +1 | 10% owner | Purchase | 150,000 | $5.59 | $838K | Form 4 |
| Nov 17, 2025 | Srinivas Akkaraju | Director | Purchase | 914 | $5.51 | $5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Srinivas Akkaraju | Director | $25.9M | $1M | Sep 8, 2026 |
| Foresite Labs, LLC | 10% owner | $7M | – | Jan 8, 2026 |
| Foresite Labs Affiliates 2021, LLC | 10% owner | $3.1M | – | Nov 19, 2025 |
| Foresite Labs Fund I, L.P. | 10% owner | $533K | – | Nov 21, 2025 |
| Sanam Pangali | Chief Legal Officer | – | $178K | Nov 2, 2026 |
| John R. Schroer | Chief Financial Officer | – | $91.7K | Nov 2, 2026 |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | – | $75.2K | Nov 2, 2026 |
| David M Goldstein | Chief Scientific Officer | – | $72.6K | Nov 2, 2026 |
| Mark Christopher Bradley | Chief Development Officer | – | $71.9K | Nov 2, 2026 |
| Jorn Drappa | Chief Medical Officer | – | $68.4K | Nov 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALMS short interest
11.03M ALMS shares are sold short. Over the last 12 reports the number of shares short went down 3%.
As of Oct 30, 2026, 11.03M ALMS shares were sold short, down 0.4% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.8 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.03M | – | -0% | 1.91M | 5.8 |
| Oct 15, 2026 | 11.08M | – | +8% | 2.28M | 4.9 |
| Sep 30, 2026 | 10.30M | – | +63% | 2.87M | 3.6 |
| Sep 15, 2026 | 6.30M | – | +12% | 7.18M | 1.0 |
| Aug 31, 2026 | 5.65M | – | -4% | 798,956 | 7.1 |
| Aug 14, 2026 | 5.85M | – | +2% | 897,557 | 6.5 |
| Jul 31, 2026 | 5.77M | – | -15% | 943,099 | 6.1 |
| Jul 15, 2026 | 6.76M | – | -53% | 1.77M | 3.8 |
| Jun 30, 2026 | 14.29M | – | +13% | 1.89M | 7.6 |
| Jun 15, 2026 | 12.66M | – | +14% | 1.45M | 8.7 |
| May 29, 2026 | 11.07M | – | -3% | 853,938 | 13.0 |
| May 15, 2026 | 11.36M | – | +1% | 806,691 | 14.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Alumis company events
Alumis filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 1, 2026.
- Sep 1, 2026AnnouncementAlumis Inc. issued a press release titled “Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE).” The Company is also filing slides presented by the Company at a webcast regarding the LUMUS Phase 2b topline results on September 1, 2026. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Aug 10, 2026AnnouncementAlumis Inc. issued a press release titled “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies”. Filing
- Jul 2, 2026VoteReported shareholder vote results. Filing
- Jun 29, 2026AnnouncementAlumis Inc. updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 30, 2026AnnouncementAlumis Inc. issued a press release titled “Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis”. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Jan 9, 2026AnnouncementThe Company entered into an underwriting agreement with Morgan Stanley & Co. LLC, Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 17,650,000 shares of the Company’s voting… Filing
- Jan 6, 2026AnnouncementAlumis Inc. issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program”. Filing
- Jan 2, 2026AnnouncementAlumis Inc. and its wholly-owned subsidiary Acelyrin, Inc. issued a Notice of Material Breach and Notification of Claim for Indemnification to Climb Bio, Inc., after Climb Bio knowingly and willfully refused to pay a $3 million Development Milestone payment due January 1, 2026 under the Asset… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Alumis financials
Famous investors that hold ALMS
3 of the 50 well-known investors we track reported holding ALMS in their latest 13F filing. The largest position is Israel Englander's, worth $24.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 3.33M | $24.6M | 0.0% | +405% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.39M | $17.6M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 64,492 | $477K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ALMS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 0.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 0.0% |
Questions about Alumis Inc. (ALMS) stock
Who owns the most ALMS stock?
The largest reported owner of Alumis Inc. (ALMS) is AyurMaya Capital Management Company, LP. In total, 199 funds and institutions reported holding ALMS at the end of Q2 2026. See the largest owners.
Are ALMS insiders buying or selling?
In the last 12 months, ALMS insiders reported 24 open-market purchases worth $36.5M and 15 sales worth $1.6M. The latest trade was on Nov 2, 2026. See every trade.
What is the short interest in ALMS?
As of Oct 30, 2026, 11.03M ALMS shares were sold short, down 0.4% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.
Which famous investors hold ALMS?
3 of the 50 well-known investors we track reported ALMS in their latest 13F filing, including Israel Englander, Ken Griffin, Paul Tudor Jones. The largest position is worth $24.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.